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DiabetesDuring mouse pancreas development, the transient expression of Neurogenin3 (Neurog3) in uncommitted pan-
creas progenitors is required to determine endocrine destiny. However it has been reported that Neurog3-
expressing cells can eventually adopt acinar or ductal fates and that Neurog3 levels were important to secure
the islet destiny. It is not known whether the competence of Neurog3-induced cells to give rise to non-
endocrine lineages is an intrinsic property of these progenitors or depends on pancreas developmental stage.
Using temporal genetic labeling approaches we examined the dynamic of endocrine progenitor differentiation
and explored the plasticity ofNeurog3-induced cells throughout development.We found that Neurog3+ progen-
itors develop into hormone-expressing cells in a fast process taking less then 10 h. Furthermore, fate-mapping
studies in heterozygote (Neurog3CreERT/+) and Neurog3-deﬁcient (Neurog3CreERT/CreERT) embryos revealed that
Neurog3-induced cells have different potential over time. At the early bud stage, failed endocrine progenitors
can adopt acinar or ductal fate, whereas later in the branching pancreas they do not contribute to the acinar lin-
eage but Neurog3-deﬁcient cells eventually differentiate into duct cells. Thus these results provide evidence that
the plasticity of Neurog3-induced cells becomes restricted during development. Furthermore these data suggest
that during the secondary transition, endocrine progenitor cells arise from bipotent precursors already commit-
ted to the duct/endocrine lineages and not from domain of cells having distinct potentialities.
© 2011 Elsevier Inc. All rights reserved.Introduction
During pancreas development it is thought that all differentiated
cells arise from a pool of multipotential progenitor cells which, through
successive cell fate choices, give rise to the exocrine (acinar and ductal)
and endocrine (islet) lineages. Characterization of the differentiation
potential and lineage relationship of these pancreatic progenitors
throughout embryogenesis is essential to understand islet cell develop-
ment and might be relevant for the generation of therapeutic beta cells
from human embryonic stem cells.
In the mouse embryo, during the initial phase of pancreas de-
velopment (E9.5–E10.5), the pancreatic epithelium is composed
of a cluster of unorganized endodermal progenitor cells expres-
sing markers such as the transcription factors Pdx1, Ptf1a, Sox9,
HNF1β or Nkx6.1 (Kawaguchi et al., 2002; Lynn et al., 2007;
Maestro et al., 2003; Ofﬁeld et al., 1996; Sander et al., 2000;
Seymour et al., 2007; Solar et al., 2009). Genetic lineage tracingolecular and Cellular Biology,
ries, F-67404 Illkirch, France.
rights reserved.studies, based on the use of transgenic mice expressing the Cre
recombinase under the control of the regulatory elements of some
of these transcription factors, demonstrated that these early pancreatic
progenitor cells can develop into exocrine cells (acinar and ductal) as
well as into the different endocrine cellular subtypes including insulin-
producing β cells (Gu et al., 2002; Kawaguchi et al., 2002; Kopp et al.,
2011; Solar et al., 2009).
From about E12 onwards, branching of the pancreatic epithelium
within the surrounding mesenchyme starts and progenitors are
then compartmentalized in the so-called tip and trunk domains
(Zhou et al., 2007). Zhou and colleagues suggested that after E14.5,
endocrine cells arise exclusively from precursors located in the em-
bryonic duct epithelium in the trunk. Recent temporal genetic fate
mapping studies of embryonic trunk cells marked by the transcrip-
tion factors Hnf1β or Sox9 gave some additional information on the
cellular origin of pancreatic endocrine and exocrine cells. Thus, after
E13.5 Hnf1β trunk cells can give rise to ductal and endocrine cells
but have lost their capacity to differentiate into acinar cells (Solar
et al., 2009). In contrast, the Sox9-domain remains multipotent until
birth and thus keeps the competence to differentiate into acinar
cells which arise from a subpopulation of Sox9 cells located at the ex-
tremity of the embryonic trunks (Kopp et al., 2011). These observa-
tions suggest that even tough they express the same marker,
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have different potentialities depending their localization and devel-
opmental stage.
It is acknowledged that the expression of the basic helix loop helix
(bHLH) transcription factor Neurogenin3 (Neurog3) implements the
endocrine program in multipotent progenitors based on the following
ﬁndings. First, inactivation of Neurog3 precludes the development of
all islet cells (Gradwohl et al., 2000; Heller et al., 2005; Lee et al.,
2002). Of note, residual glucagon expressing cells have been reported
before E12.5 in one Neurog3 knock out line (Wang et al., 2008). Sec-
ond, forced expression of Neurog3 in Pdx1-positive progenitors re-
sults in premature endocrine differentiation (Apelqvist et al., 1999;
Johansson et al., 2007; Schwitzgebel et al., 2000). Interestingly the
competence of these pancreatic progenitors to contribute to the dif-
ferent endocrine cell types upon Neurog3 stimuli varies during em-
bryogenesis (Johansson et al., 2007). Third, lineage tracing
experiments demonstrated that all endocrine cells derive from
Neurog3-expressing progenitor cells (Gu et al., 2002; Heller et al.,
2005; Schonhoff et al., 2004). Endocrine committed Neurog3+
cells are essentially post-mitotic (Miyatsuka et al., 2011) and in
vivo clonal analysis support that they are unipotent, meaning that
a single Neurog3+ cell gives rise to a single islet cell-type (Desgraz
and Herrera, 2009). The later implies that although they express the
same marker (Neurog3+) islet progenitor cells are a heterogeneous
population of cells. Neurog3 thus marks a population of progenitors
committed to the endocrine lineage that can be found initially as scat-
tered cells localized in the pancreatic bud and later in the trunk
epithelium.
Despite the central role of Neurog3 in the speciﬁcation of pancre-
atic islets, recent studies suggest that Neurog3-positive progenitors
might eventually adopt alternative fates (Schonhoff et al., 2004;
Wang et al., 2009b). Furthermore, it appeared that Neurog3 expres-
sion has to reach a certain threshold to consolidate the endocrine
fate (Wang et al., 2009b). The latter conclusion has been drawn
by Wang and colleagues using a lineage tracing approach based
on the expression of constitutive Cre recombinase in Neurog3-
expressing cells. They showed that in total absence of Neurog3 and
to a lower extent in low Neurog3 dosage, Neurog3-induced progen-
itors adopt an acinar or ductal destiny. Thus, these data imply that
endocrine progenitors arise from multi or at least bipotent precur-
sors. The identity and potentiality of such precursor cells, lying im-
mediately upstream of Neurog3-positive progenitor cells, are still
elusive. It is also unclear whether the competence of Neurog3-
expressing cells to give rise to non-endocrine lineages depends on
the developmental stage.
In this study our aim was to explore the plasticity of Neurog3-
induced cells throughout development in heterozygous and more
particularly in Neurog3-deﬁcient conditions. To address this question
we used an inducible Cre/lox lineage tracing approach. We took ad-
vantage of the Neurog3CreERT/+ mice (Wang et al., 2009a) where
cells transcribing Neurog3 gene can be genetically marked at a speciﬁc
developmental time point and the ability of the tagged progenitor to
contribute to a speciﬁc lineage determined at later stages. Important-
ly, this mouse model also allows the identiﬁcation and tracking of
Neurog3-induced progenitors in Neurog3 homozygous null mutant
mice. Thus, cells which have been instructed to turn on the Neurog3
gene but cannot adopt an endocrine destiny because they fail to ex-
press Neurog3 transcription factor can be labeled and studied. Our
hypothesis was that information on the alternative destiny of these
Neurog3-induced cells during pancreas development would provide
important insight on the competence/plasticity of the failed endo-
crine progenitor.
Using this mouse model, we show that islet cell progenitors differ-
entiation into hormone-producing cells is a fast process leading to
hormone expression within 10 h. In absence of Neurog3 expression,
after E12.5 Neurog3-induced cells do not delaminate and differentiateinto ductal cells, whereas before E12.5 Neurog3-induced cells differ-
entiate into acinar or ductal cells. Neurog3-induced cells thus lose
their acinar potential during development. These results suggest
that islet progenitor cells arise from multipotent precursors in
the pancreatic bud. However starting from E12.5, endocrine cells
arise from bipotent precursor cells located in the trunk already
committed to the ductal/endocrine lineage. Furthermore these
data strongly support the bipotent nature of trunk precursor cells
rather then being individual precursors with a ductal or endocrine
potentiality.
Results
Neurog3-induced cells differentiate into hormone-expressing cells in
10 h in mouse embryos
To characterize the biology and address the potential of Neurog3-
induced cells at different developmental stages, we used Neurog3CreERT
knock-in mice (Wang et al., 2008). We ﬁrst characterized the accuracy
of this model for temporal lineage tracing studies. In Neurog3CreERT/+
mice, the Tamoxifen inducible CreER™ recombinase (hereafter referred
to as CreERT) replaces theNeurog3 coding sequence (Fig. 1a). Bymating
these mice with the Cre reporter mice R26RlacZ (Soriano, 1999) or
R26ReYFP (Srinivas et al., 2001), a pulse of Tamoxifen allows the genetic
labeling of Neurog3-induced cells and their progeny by constitutive ex-
pression of the β-galactosidase (β-gal) or the enhanced yellow ﬂuores-
cent protein (eYFP). Furthermore, by generating Neurog3CreERT/CreERT
homozygous mice, it is possible to genetically tag and follow the alter-
native fate ofNeurog3-induced cells, which do not express the proendo-
crine transcription factor.
Pancreatic endocrine progenitor cells are characterized by the
transient expression of Neurog3. During their differentiation into
the various islet cell types, Neurog3 expression is turned off before
the onset of hormone expression. Although, the knock-in approach
ensures a faithful expression of the CreERT in Neurog3+ cells, differ-
ences in stability between Neurog3 and CreERT proteins could result
in misinterpretation of the identity of the labeled cells (e.g. labeling
of post-Neurog3 cells if CreERT is more stable than Neurog3). We
thus ﬁrst veriﬁed the overlapping expression of CreERT and Neurog3
proteins on E15.5 pancreas sections. As expected, cytoplasmic CreERT
expression is detected in almost all Neurog3+ cells, and Neurog3−/
Cre+ cells were rarely observed (Fig. 1b). To genetically label
Neurog3-induced cells at a precise time point, Neurog3CreERT/+ fe-
males were mated with R26ReYFP males and injected with a single
dose (1 mg) of 4-hydroxy-Tamoxifen (4-OH-TM) at E15.5. Nuclear
translocation and robust expression of CreERT in Neurog3+ cells
were observed after 4-hydroxy-Tamoxifen (4-OH-TM) injection
(Fig. 1c), which advocates that recombination will very likely occur
in Neurog3+ cells. The presence of some CreERT+/Neurog3− nuclei
(Fig. 1c) suggests that CreERT perdures after Neurog3 is turned off.
Importantly, we never observed CreERT expression in hormone-
positive cells in uninduced or 4-OH-TM treated embryos (Fig. 1d, e).
Previous publications reported that Tamoxifen activated CreERT is
translocated in the nucleus and recombination initiated within 6 h
(Ahn and Joyner, 2004) (Hayashi and McMahon, 2002). In agreement
with these ﬁndings, eYFP-labeled cells can already be detected in the
pancreas 10 h after 4-OH-TM injection (Fig. 2b), demonstrating that
recombination is effective in this time frame (shorter period were
not tested). Two populations of eYFP-tagged cells can be observed
10 h after 4-OH-TM injection: eYFP+/Neurog3+ cells, which are en-
docrine progenitor cells and eYFP+/Neurog3−, likely corresponding
to differentiating endocrine cells. Importantly, 24 h after 4-OH-TM in-
jection, most of eYFP+ cells no longer express Neurog3 (97.1±0.57%,
Fig. 2c), but express endocrine transcription factors e.g. Insm1, MafB
and MafA (Fig. S1c), demonstrating that these eYFP+/Neurog3−
cells are differentiating post-Neurog3 endocrine cells. To determine
Fig. 1. Temporal lineage tracingwithNeurog3CreERTmouse. (a) Schematic of theNeurog3CreERT Knock-in and Cre reporter alleles andmating scheme. A Tamoxifen-inducible Cre recombinase
(CreER™) expressed speciﬁcally from theNeurog3 locus removes the “STOP” cassette in the Rosa26 locus uponTamoxifen treatment, allowing constitutive expression of theβ-gal or the eYFP.
(b–e) Representative confocal images showing immunoﬂuorescence for Neurog3, Cre and islet hormones on cryosections of E15.5 (b–d) or E16.5 (e) Neurog3CreERT/+ pancreas, untreated
(b, d) or 24 h after 4-OH-Tamoxifen (4-OH-TM) treatment (c, e). (b–c)Nuclear translocation of CreERT is activated inNeurog3+ cells upon4-OH-TM injection. (d–e) The CreERT recombinase
is not expressed in hormone-producing cells. Arrows point to double stained cells. *, this cell does not stain for DAPI (not shown), thus the optical section does not cross through the nucleus
and the red staining corresponds to cytoplasmic CreERT (b–c) Scale bar 20 μm. (d–e) Scale bar 50 μm.
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from a Neurog3+ progenitor, we analyzed Insulin, Glucagon and Pan-
creatic Polypeptide (PP) expression in theNeurog3+ cells progeny. 24 hand even 10 h after 4-OH-TM administration, all these hormones are
commonly expressed in eYFP+ cells (Fig. 2d–i). At 10 h, 89.5% of
eYFP+ cells coexpress Insm1 while 4.5% are hormone-positive (Fig.
Fig. 2. Endocrine subtype speciﬁcation in 10 h. (a) Schematic of the lineage tracing experiment. (b–i) Confocal immunoﬂuorescence images of Neurog3CreERT/+;R26ReYFP embryonic
pancreas, 10 h (b, d–f) and 24 h (c, g–i) after 4-OH-TM injection. Neurog3 is still expressed in some eYFP+ cells 10 h (b, arrows), but not 24 h after injection (c) demonstrating that
Neurog3 is expressed less than 24 h in endocrine progenitors. Insulin (d), Glucagon (e, arrow) and PP (f) hormones are detected in Neurog3 descendants 10 h after the labeling of
Neurog3 expressing cells. (j) Kinetic of an endocrine progenitor cell differentiation. (b–c) Scale bar 50 μm. (d–i) Scale bar 10 μm.
280 A. Beucher et al. / Developmental Biology 361 (2012) 277–285S1d) suggesting that the later derive from Neurog3+ cells where re-
combination occurred just before Neurog3 is turned down and that dif-
ferentiation does not occur in less then 10 h. Taken together our dataindicate that endocrine differentiation occurs with an initial transient
expression of Neurog3, which lasts less than 24 h, followed within
10 h by hormones synthesis (Fig. 2j).
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resulting in abnormal morphogenesis of the trunk epithelium
To gain insight into the potentiality of Neurog3-deﬁcient cells
we ﬁrst characterized the fate of the Neurog3-induced cells in
Neurog3CreERT/CreERT; R26RlacZ embryos at E15.5, when numerous
Neurog3-positive cells are found in the trunk epithelium. Pregnant
mice were injected with 4-OH-TM at E15.5 and embryos were har-
vested one day later (Fig. 3a). The overall number of labeled cells
varied greatly among the embryos, likely due to variation in the avail-
ability/efﬁcacy of 4-OH-TM. However, we did not observe a statistically
signiﬁcant difference between the number of genetically labeled cells
between heterozygous and Neurog3-deﬁcient embryos (Fig. S4).
At E16.5, we detected X-gal+ cells within the trunk epithelium of
Neurog3CreERT/+; R26RlacZ control and Neurog3CreERT/CreERT; R26RlacZ
embryos (Fig. 3a–f). In the control pancreas, 24 h after 4-OH-TM injec-
tion, X-gal+ cells have started to delaminate from the trunk epithelium
(Fig. 3c, e). In contrast, in Neurog3-deﬁcient pancreas, labeled cellsFig. 3. Neurog3-induced progenitors divide and do not migrate out of the pancreatic epi-
thelium inNeurog3-deﬁcient mice. (a–b)Wholemount X-gal staining of β-Gal expressing
cells in E16.5 pancreas, 24 h after 4-OH-TM injection. (c–f) X-gal staining (blue) and im-
munohistochemistry for Pdx1 (brown). e and f are higher magniﬁcations of boxed area
in c and d respectively. Neurog3-mutant cells (d, f, blue cells) do not delaminate from
the epithelium in contrast to the progeny of Neurog3CreERT/+ control cells (c, e, arrows)
resulting into cystic like epithelial structures (d, f). (g–h) Confocal immunoﬂuorescence
images of heterozygous and Neurog3-mutant E16.5 pancreas sections immunostained
with anti-Ki67 and anti-Cre antibodies, 10 h after 4-OH-TM injection. Whereas the Neu-
rog3+ (CreERT) cells are mainly post-mitotic (g), most of the Neurog3-mutant cells
(CreERT) expressed the proliferativemarker Ki-67 (h). Bottom panels are highermagniﬁ-
cations of the boxed area in g and h. Scale bar 50 μm.(X-gal+) are stuck in the trunk (Fig. 3d, f). Delamination failure of
labeled cells in absence of Neurog3 transcription factor are even more
obvious 48 h after 4-OH-TM injection (Fig. 4 compare h and i). These re-
sults demonstrate that Neurog3 is necessary for the delamination of
developing islet cells from the pancreatic epithelium. Because Neurog3
activated cells have not delaminated in the mutants and still expressed
Pdx1 (Fig. 3d, f) we postulated that these cells could maintain a prolif-
erative capacity. Indeed, in the control pancreas, most if not all of the
CreERT+ cells are Ki-67− (Fig. 3g), indicating that endocrine progeni-
tors are mainly post-mitotic. In contrast, in the absence of Neurog3
expression, almost all the CreERT+ cells where Neurog3 transcrip-
tion has been activated are dividing (Fig. 3h) in agreement with a re-
cent report showing the importance of Neurog3 in the regulation of
cell cycle exit (Miyatsuka et al., 2011). Accumulation of such dividing
cells that cannot delaminate and engage an endocrinogenic differentia-
tion program resulted into abnormal morphogenesis of the trunk epi-
thelium with cystic like structures (Fig. 3f and data not shown). Thus
theseﬁndings demonstrate thatNeurog3 is induced in proliferating pre-
cursors before cell cycle exit and delamination.
Neurog3-induced cells have the potential to develop into ductal cells
throughout development in Neurog3-deﬁcient mice
We next determined the differentiation potentiality of Neurog3-
induced cells in Neurog3-deﬁcient mice throughout pancreas develop-
ment. Neurog3CreERT/+ and Neurog3CreER/T ; R26ReYFP mice were crossed
and pregnant females injected with a single dose of 4-OH-TM at E10.5,
E11.5, E12.5 andE15.5 (Figs. 4 and 5). Embryoswere essentially analyzed
at E17.5. When probing the endocrine lineage we showed that from
E10.5 to E12.5 Neurog3+ cells can be efﬁciently labeled and give rise to
α-cells, or at later stages to β-cells in heterozygous mice (Fig. 5a, c, e,
g) in agreement with previous studies (Johansson et al., 2007). As
expected endocrine cells did not develop in Neurog3CreERT/CreERT;
R26ReYFP embryos (Fig. 5b, d, f and not shown). We ﬁrst addressed the
ductal potentiality of Neurog3-deﬁcient cells. Consistently with the data
described above, using the R26RLacZ reporter, in control embryos (Neu-
rog3CreERT/+; R26ReYFP), Neurog3+ cell descendants (EYFP+) have dela-
minated from the trunk epithelium to form islets (Fig. 4h). In contrast, in
absence of Neurog3 (Neurog3CreERT/CreERT; R26ReYFP), the progeny of
Neurog3-induced cells is still located in the trunk and expresses Muc1
and Sox9, two duct cell markers at this late embryonic stage (Fig. 4i,
S2g). When labeled at E15.5, most of the eYFP+ cells progressively lose
Pdx1 expression in Neurog3-deﬁcient embryos (Fig. S2j, l) further sup-
porting that the tagged pancreatic progenitors differentiate into duct
cells. Importantly, ductal destiny was observed for Neurog3-induced
cells in KOmice independently of the embryonic stagewhen progenitors
have been genetically labeled (Fig. 4c, e, g). In heterozygous mice,
Neurog3-induced cells can differentiate into duct cells essentially before
E12.5 but very rarely after (Fig. 4b, c and S2b, c and not shown). Theses
results demonstrate that in Neurog3-deﬁcient mice, Neurog3-induced
cells can give rise to ductal cells during the ﬁrst and secondary transition
period.
Neurog3-induced cells differentiate into acinar cells only before E12.5
Previous lineage tracing of Neurog3+ cells in transgenic mice have
reported that a small fraction of acinar cells can arise from Neurog3+
cells (Gu et al., 2002; Schonhoff et al., 2004; Wang et al., 2009b). Here
we examined the acinar potentiality of Neurog3-induced cells at various
developmental stages. In absence of Neurog3, when pregnant females
were injected with 4-OH-TM at E10.5 or E11.5, Neurog3-induced cells
differentiate into many amylase-positive acinar cells (89.6±1.67% of
eYFP cells are acinar cells when injected at E11.5 in Neurog3CreERT/CreERT;
R26R
eYFP
mice, Fig. 5b, d). Importantly further experiments revealed that
by E12.5, Neurog3-deﬁcient cells lost this competence to differentiate
into acinar cells (Fig. 5f, h). When the same analysis was performed at
Fig. 4. Reallocation ofNeurog3-inducedprogenitor cells into ductal cells inNeurog3-deﬁcient
mice throughout development. (a) Schematic of the lineage tracing experiment. (b–i) Con-
focal immunoﬂuorescence images of E17.5 pancreas sections fromheterozygous (Neurog3-
CreERT/+; R26ReYFP), or Neurog3-deﬁcicient mice (Neurog3CreERT/CreERT; R26ReYFP/+) treated
with 4-OH-TM at various time points between E10.5 and E15.5. Neurog3-induced progeny
differentiate into Muc1+ duct cells at every stage analyzed in Neurog3-deﬁcient mice
(c, e, g, i) whereas Neurog3-induced cells differentiate into Muc1+ cells only before E12.5
in heterozygotes (b, d). Arrows point to eYFP+/Muc1+ cells. (b–i) Scale bar 20 μm.
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any labeled acinar cell (Fig. 5i, j). Tracing of Neurog3 heterozygous cells
labeled between E10.5–E11.5 showed that they could similarly differen-
tiate into acinar (Fig. 5a’) cell lineage. However, such a non-endocrine
destiny for a Neurog3+ cells in heterozygotes embryos was a rare
event in our experimental system compared to homozygotes. These
ﬁndings are consistent with previous data suggesting that reduced pro-
duction of Neurog3 promotes acinar cell differentiation (Wang et al.,
2009b). Importantly in heterozygous cells, similarly to Neurog3-
deﬁcient cells, the acinar fate was restricted to Neurog3-inducedprogenitors born before E12.5 (Fig. S3 compare a and b). Interestingly,
we noticed that when Neurog3-induced cells were labeled at E10.5 or
E11.5 (but not at E12.5) in Neurog3-deﬁcient embryos, numerous clus-
tered eYFP-labeled cells were subsequently found at E17.5 (Fig. 5 com-
pare b, d to f and S3 compare b to d), suggesting a clonal origin of
YFP+ acinar cells. Labeled acinar clusterswere also found in control Neu-
rog3CreERT/+ embryos in similar experiments but much fewer cells were
labeled (Fig. 5a’ and S3a). Further supporting a clonal origin, analysis of
pancreas at E12.5 two days after injection, revealed only isolated
eYFP+ cells (Fig. 5k–n). We thus postulated that clusters of acinar cells
arose from single Neurog3-expressing cells, which adopted an acinar
fate and later proliferated. Taken together, our data demonstrate that
during the primary transition, Neurog3-induced cells can give rise to ac-
inar cells. However, at E12.5 and thereafter, whenNeurog3-induced cells
are located in the trunk domain of the branching epithelium, they loose
their capacity to differentiate into the acinar lineage.
Discussion
During pancreas embryogenesis, all hormone-expressing endo-
crine cells differentiate from endocrine progenitor cells marked by
the transcription factor Neurog3, which is strictly required for endo-
crine commitment. However, the plasticity and the biology of
Neurog3-induced cells during development remain incompletely
characterized. Therefore, we took advantage of a mouse model
where Neurog3-induced cells can be genetically labeled at different
time points to address these questions. Our experiments ﬁrst revealed
a time window of about 34 h for islet progenitor cell differentiation in
vivo. Second, we demonstrate that Neurog3 is required for delamina-
tion of the developing islet cells. Third, we show that Neurog3-
induced cells have different potentiality during pancreas development
(Fig. 6). Importantly, we provide evidence that after the secondary tran-
sition islet progenitor cells arise through truly bipotent duct/endocrine
progenitor cells.
Kinetic of endocrine differentiation
Using temporal lineage tracing, we have determined that Neurog3
protein expression lasts less than 24 h in pancreatic endocrine pro-
genitors. Insulin, glucagon or PP peptides are detected only 10 h
after Neurog3 expression is turned off. Previous studies based on
data obtained with a Neurog3-timer mice suggest that Neurog3 was
transcribed for about 6 h in the endocrine progenitors, and that it
takes another 12 h for these cells to express insulin or glucagon tran-
scripts (Miyatsuka et al., 2009). In the later study, differentiation was
analyzed in dissociated islet progenitor cells maintained in culture.
Variation in the time window for Neurog3 expression and hormone
synthesis between both studies might thus result from differences be-
tween mRNA (Miyatsuka et al., 2009) and protein half lives (this
study). Alternatively culture conditions might accelerate the develop-
ment of islet cells. Taken together our data imply that, starting from
the beginning of Neurog3 expression, it takes less than 34 h for the
generation of a hormone-producing cell in the mouse embryo.
Neurog3 is necessary for the migration of developing islet cells
In the embryonic pancreas, endocrine progenitors arise within the
pancreatic epithelium. Developing endocrine cells subsequently de-
laminate from the epithelium and migrate into the mesenchyme
where they aggregate into clusters, the islets of Langerhans. Our
data clearly demonstrate that this process is strictly dependent on
Neurog3. Indeed in absence of Neurog3, we showed that failed endo-
crine progenitors do not migrate from the pancreatic epithelium, ulti-
mately leading to perturbed trunk morphogenesis. In agreement with
our ﬁndings, Magenheim et al. (2011) described recently reduced
branching and enlarged pancreatic duct-like structures in Neurog3-
Fig. 5. Neurog3-induced cells can give rise to acinar cells only before E12.5. Confocal immunoﬂuorescence images of heterozygous and Neurog3-mutant embryonic pancreas sections
at E12.5, E17.5 or E19.5, from pregnant mice injected with 4-OH-TM between E10.5 and E15.5. (a–c): E10.5 and E11.5 Neurog3+ progenitors give rise essentially to endocrine cells
(a, c) and rarely differentiate into Amylase+ acinar cells (a’), in contrast to Neurog3-deﬁcient mice where many Neurog3-induced cells differentiate into acinar cells (b, d). From
E12.5 Neurog3+ progenitors differentiate only into endocrine cells (e, g) and Neurog3-deﬁcient cells have lost their competence to differentiate into acinar cells (f, h, j). (k–n) At
E10.5, Neurog3-induced cells can differentiate into Cpa1+ cells in heterozygous and Neurog3 deﬁcient mice. (m, n) Higher magniﬁcation of insets in k’ and l. Yellow and blue arrows
point to eYFP labeled acinar and endocrine cells respectively. Red arrows point to β-gal expressing cells. Scale bar 20 μm.
283A. Beucher et al. / Developmental Biology 361 (2012) 277–285deﬁcient mice that could result from delamination failure. Consistent-
ly, it has been demonstrated, that Neurog3 is sufﬁcient to trigger cell
delamination from the chicken endoderm (Gouzi et al., 2011;
Rosenberg et al., 2010). Interestingly Gouzi et al. (2011) provide
some evidence that Neurog3 induces an Epithelial-to Mesenchymal
Transition (EMT), by regulating at the post-transcriptional the level,
the expression of the transcription factor Snail2, known to trigger
EMT (Nieto, 2009). Thus, Neurog3 is both necessary and sufﬁcient
to trigger the delamination of developing endocrine progenitors
from the pancreatic epithelium.
During the secondary transition islet cells arise frombipotent duct/endocrine
progenitor cells and not from domain of cells having distinct potentialities
Recent lineage tracing experiments demonstrated that during the
secondary transition, Hnf1β+ early duct cells (also called embryonic
cords) differentiate exclusively into duct or endocrine cells (Solar et
al., 2009). From these results, it is impossible to conclude whether
the endocrine and ductal lineages arise from a common bipotent pro-
genitor or from distinct progenitors expressing Hnf1β+. In the same
line, although Hnf1β and Sox9 expressions overlap extensively inthe embryonic cords, it has been reported that Sox9+ cells can give
rise to acinar cells (in addition to endocrine and duct cells) until
birth, likely from terminal duct progenitors which do not express
Hnf1β. Thus these temporal cell-tracing experiments revealed that
domains of progenitor cells of the early duct epithelium, and expres-
sing a speciﬁc maker, differ in their developmental potential. At the
single cell level however there is no formal demonstration that a
given Hnf1β or Sox9+ progenitor is bi- or multi-potent. Here we
providence evidence that after progenitor cell compartmentalization
into tip and trunk domains (around E12.5) and in absence of Neurog3
expression, Neurog3-induced trunk/cord cells differentiate solely into
duct cells. In control experiments performed in heterozygotes, the
vast majority if not all Neurog3+ cells adopt an endocrine destiny.
Thus these data strongly support the hypothesis that islet progenitors
indeed arise from bipotent duct/endocrine precursors through a bina-
ry cell fate decision during the secondary transition. Interestingly be-
fore E12.5, Neurog3-induced cells still have the potential to
differentiate into acinar cells (as well as duct cells). This implies
that during pancreas development, the ﬁrst endocrine cells differenti-
ate from multipotent acinar/duct/endocrine progenitors or at least
from bipotent endocrine/acinar or endocrine/duct progenitors. After
Fig. 6. Summary of the lineage tracing experiments deﬁning the destiny ofNeurog3-induced
cells in heterozygous andNeurog3-deﬁcientmice. A, Acinar cell; D, duct cell; E, endocrine cell.
Full line: main differentiation ways. Dashed line: rare events.
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clusively through bipotent duct/endocrine progenitors.
The competence of Neurog3 heterozygous cells to give rise to non-endocrine
cells is restricted to the primary transition period
Previous studies provide evidence that during pancreas develop-
ment, Neurog3 gene dosage controls endocrine versus exocrine cell
fate destiny in Neurog3-expressing cells (Wang et al., 2009b). This
conclusion was based on the observation that mice heterozygous for
Neurog3 have a reduced production of Neurog3 protein as well as a
higher number of Neurog3+ cells giving rise to acinar as well as ductal
cells compared to wild-type. Therefore, only cells expressing sufﬁ-
ciently high levels of Neurog3 would differentiate into endocrine
cells. The current temporal lineage tracing study revealed that
Neurog3-positive cells, in Neurog3CreERT/+ mice, are only competent
to differentiate into acinar or duct cells before E12.5. We only excep-
tionally observed rare duct cells and never any acinar cell arising from
Neurog3-expressing cells after this stage. This implies that Neurog3
gene dosage operates to regulate endocrine versus non-endocrine
cell allocation in competent cells present during the primary transi-
tion period. Thus, cells born before E12.5 and unable to reach this
Neurog3 threshold would be at the origin of exocrine cells arising
from Neurog3-expressing cells observed in this study and in constitu-
tive lineage tracing experiments that have used Neurog3 driven Cre
transgenic mice (Cras-Meneur et al., 2009; Gu et al., 2002;
Schonhoff et al., 2004; Wang et al., 2009b). In line with these observa-
tions, deletion of HNF6 in endocrine progenitors also increases alloca-
tion of progenitor cells to the exocrine lineage (Zhang et al., 2009). As
HNF6 is known to activate transcription of Neurog3 (Jacquemin et al.,
2000), HNF6 function could be to sustain Neurog3 expression and
promote endocrine destiny. Thus Neurog3-induced cells have certain
plasticity before E12.5 and can give rise to endocrine and eventually
acinar or duct cells, whereas after this stage they are strictly commit-
ted to the endocrine lineage. In good agreement with our ﬁndings it is
also from E12.5 that an antagonistic repressive activity of Nkx6 and
Ptf1a transcription factors has been suggested to restrict multipotent
pancreatic progenitors to ductal/endocrine versus acinar fates
(Schaffer et al., 2010). Thus, Nkx6.1 and 6.2 could determine compe-
tent bipotent duct/endocrine progenitors that will differentiate into
endocrine cell upon Neurog3 expression.Recent strategies to generate therapeutic beta cells from embryonic or
induced pluripotent stem cells are essentially based on the recapitulation
of embryonic differentiation programs. Using this approach, immature
beta cells have been obtained from human embryonic stem cells
(D'Amour et al., 2006). It is not knownwhether the kinetic of differentia-
tion inﬂuences the functionality of the insulin-expressing cells obtained.
Similarly the importance of the cellular mechanism underlying beta cell
generation has not been studied. Our data suggest that during pancreas
development islet progenitors can be generated from progenitors with
distinct potentialities. Thus do hES-derived Neurog3+ cells derive from
multipotent progenitors or bipotent endocrine/ductal progenitors? It is
tempting to speculate that hES-derived insulin-expressing cells resemble
the immature endocrine cells generated in the early pancreatic bud from
metastable Neurog3+ cells originating from multipotent progenitors.
Therefore, novel strategies could focus on mimicking the generation of
beta cells from bipotent endocrine/ductal trunk progenitors occurring
during the secondary transition. Recently pancreatic tubulogenesis has
been suggested to promote exposition of trunk progenitors to a speciﬁc
microenvironment important for appropriate cell fate determination
(Kesavan et al., 2009). Identiﬁcation of the conditions to reproduce such
a niche might be the key for the generation of bipotent endocrine/ductal
progenitors and the subsequent differentiation of functional beta cells in
vitro.
Material and methods
Mouse strains and tamoxifen treatment
The Neurog3CreERT/+ strain was described previously (Wang et al.,
2008). Neurog3CreERT/+ females were mated with Neurog3CreERT/+;
R26ReYFP/eYFP or Neurog3CreERT/+; R26RlacZ/lacZ males in order to generate
mutant embryosNeurog3CreERT/CreERT; R26ReYFP/+orNeurog3CreERT/CreERT;
R26RlacZ/+. The noon of the day of a vaginal plug was designated as E0.5.
R26RlacZ/+ and R26ReYFP/+ mouse lines were generous gifts from P.
Soriano and F. Costantini. Pregnant females were injected intraperi-
toneally with 1 mg 4-hydroxy-Tamoxifen (4-OH-TM) at indicated em-
bryonic stages. 4-OH-TM (H-6278 Sigma) was prepared at 10 mg/mL in
10% ethanol and 90% corn oil.
β-Galactosidase activity detection
For 5-bromo-4-chloro-3-indolyl-D-galactoside (X-gal) staining,
tissues were ﬁxed for 30 min at room temperature in 0.2% glutaralde-
hyde, 5 mM EGTA, 2 mM MgCl2 in 0.1 M sodium phosphate pH 7.3,
washed three times for 10 min in LacZ wash buffer (2 mM MgCl2 in
0.1 M sodium phosphate pH 7.3, 0.02% NP-40) and whole mount
staining was performed in a solution containing 1 mg/ml X-Gal,
5 mM potassium ferrocyanide and 5 mM potassium ferricyanide in
LacZ wash buffer at 37 °C for 4 h. After staining, samples were washed
in PBS, post-ﬁxed with Paraformaldehyde (PFA) 4% at 4 °C and pro-
cessed for wax sections.
Immunohistochemistry
Digestive tracts were ﬁxed in PFA 4%, o/n at 4 °C, washed in PBS,
equilibrated in 20% sucrose at 4 °C and embedded in OCT compound.
Immunohistochemistry analyses were performed on 10 to 14 μm
cryosections.
The following primary antibodies were used: guinea pig anti-
Neurog3 at 1:1000 (provided by M. Sander, University of California —
San Diego, La Jolla, CA, USA), rabbit anti-Cre at 1:2000 (Eurogentec Cov-
ance), rabbit anti-GFP at 1:500 (Molecular Probe, A-6455), rat anti-E-
cadherin at 1:200 (Invitrogen), guinea pig anti-Insulin at 1:1000
(Linco), guinea pig anti-Glucagon at 1:2000 (Linco), guinea pig anti-
PP at 1:1000 (Linco), mouse anti-Ki-67 at 1:100 (Novo castra), Arme-
nian hamster anti-Muc1 at 1:500 (Thermo), goat anti-Sox9 at 1:50
285A. Beucher et al. / Developmental Biology 361 (2012) 277–285(Santa Cruz), guinea pig anti-Pdx1 at 1:500 (provided by C. Wright,
Vanderbilt University, Nashville, TN, USA), goat anti-Amylase at 1:200
(Santa Cruz), rabbit anti-Amylase at 1:1000 (Sigma), chicken anti-β-
galactosidase at 1:5000 (Abcam), Goat anti-CPA1 at 1:200 (R&D sys-
tems), guinea pig anti-Insm1 at 1:500 (provided by C. Birchmeier,
Max-Delbrück-Centrum for MolecularMedicine, Berlin, Germany), rab-
bit anti-MafA at 1:2000 (Bethyl) and rabbit anti-MafB at 1:2000 (pro-
vided by R. Stein, Vanderbilt University, Nashville, TN, USA).
Secondary antibodies conjugated to DyLyght-488, DyLight-549 and
DyLight-649 (Jackson ImmunoResearch Laboratories) were used at
1:500. For mouse anti-Ki-67, signal ampliﬁcation was performed using
biotin anti-mouse coupled antibody at 1:200 (Vector Laboratories)
and streptavidin-Cy3 conjugate at 1:500 (Molecular Probes). For anti-
β-galactosidase immunoﬂuorescence reactions were performed with
tyramide signal ampliﬁcation (TSA) (PerkinElmer). Nuclei were stained
with DAPI and slidesweremounted in Aqua-Poly/Mount (Polysciences).
Immunohistochemistry was also performed on wax sections after
whole mount X-gal staining and the primary antibodies were detected
with the ABC immunoperoxidase/DAB system (Vector Lab. Inc., USA)
Supplementary materials related to this article can be found online
at doi:10.1016/j.ydbio.2011.10.025.
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